Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-adp ribose polymerase (parp) inhibitors: a real-world analysis of postmarketing surveillance data

HIGHLIGHTS

SUMMARY

Analysis of the FAERS and EV databases provides a broader perspective for detecting AEs associated with newly approved drugs and rare AEs that occur in the real world (Pinheiro et_al, 2016; Meng et_al, 2019). A series of high-level evidence-based medical studies showed that PARP inhibitors have significant clinical benefits in patients with ovarian cancer (Coleman et_al, 2017; Gonzalez-Martin et_al, 2019; Ray-Coquard et_al, 2019), breast cancer (Litton et_al, 2018; Tutt et_al, 2021), pancreatic cancer (Golan et_al, 2019) and prostate cancer (Hussain et_al, 2020). A few randomized controlled trials (RCTs) have reported . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.